<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857827</url>
  </required_header>
  <id_info>
    <org_study_id>QC-202</org_study_id>
    <nct_id>NCT04857827</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Tolerability of QLS-101 in NTG</brief_title>
  <official_title>A Randomized Active-controlled Study to Evaluate Safety and Tolerability of QLS-101 Versus Timolol Preservative Free Ophthalmic Solution in Subjects With Normal Tension Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qlaris Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qlaris Bio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized active-controlled multi-site double-masked study to evaluate the safety and&#xD;
      tolerability of 2 concentrations of QLS-101 versus timolol maleate Preservative Free (PF)&#xD;
      0.5% ophthalmic solution in subjects with normal tension glaucoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Study subjects, Investigators and their staff, and Sponsor personnel involved with the conduct and monitoring of the study will be masked to the IP identity until after the final database is locked. IPs will be provided in identical-appearing pouches to maintain masking.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular safety</measure>
    <time_frame>86 days</time_frame>
    <description>Number of participants with treatment-related adverse events will be monitored</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular hypotensive efficacy</measure>
    <time_frame>14 days</time_frame>
    <description>Number of participants with intraocular pressure reduction from baseline will be calculated</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Normal Tension Glaucoma</condition>
  <arm_group>
    <arm_group_label>QLS-101 ophthalmic solution 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ophthalmic solution one time daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol maleate PF 0.5% ophthalmic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ophthalmic solution one time daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QLS-101 ophthalmic solution 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ophthalmic solution one time daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLS-101</intervention_name>
    <description>Ophthalmic solution daily dosing for 14 days.</description>
    <arm_group_label>QLS-101 ophthalmic solution 1.0%</arm_group_label>
    <arm_group_label>QLS-101 ophthalmic solution 2%</arm_group_label>
    <arm_group_label>Timolol maleate PF 0.5% ophthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Visual acuity +1.0 logMAR or better&#xD;
&#xD;
          2. Willing to give informed consent&#xD;
&#xD;
          3. Ability to washout from current intraocular pressure lowering medications -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. All secondary glaucomas&#xD;
&#xD;
          2. Previous glaucoma intraocular or laser surgery (selective laser trabeculoplasty&#xD;
             permitted when done 18 months or longer from Screening)&#xD;
&#xD;
          3. Refractive surgery&#xD;
&#xD;
          4. Ocular infection or inflammation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qlaris Bio</last_name>
    <role>Study Chair</role>
    <affiliation>Wellesley, MA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl St, John</last_name>
    <phone>508-514-9034</phone>
    <email>cstjohn@qlaris.bio</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Brandano</last_name>
    <phone>978-930-2103</phone>
    <email>lbrandano@qlaris.bio</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://qlaris.bio/pipeline</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

